{"id":457,"date":"2023-03-28T09:37:16","date_gmt":"2023-03-28T09:37:16","guid":{"rendered":"https:\/\/www.cic.vc\/?p=457"},"modified":"2024-04-16T12:13:24","modified_gmt":"2024-04-16T12:13:24","slug":"bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates","status":"publish","type":"post","link":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/","title":{"rendered":"Bicycle Therapeutics announces a strategic collaboration with Novartis"},"content":{"rendered":"<ul>\n<li><span class=\"text-small\">Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radioligand therapies in oncology<\/span><\/li>\n<li><span class=\"text-small\">Bicycle will receive a $50 million upfront payment as well as potential milestones and tiered commercial royalties<\/span><\/li>\n<\/ul>\n<p><span class=\"text-small\"><a href=\"https:\/\/www.bicycletherapeutics.com\/\" target=\"_blank\" rel=\"noopener\">Bicycle Therapeutics<\/a>\u00a0plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that it has entered into a strategic collaboration agreement with Novartis to develop, manufacture and commercialize Bicycle\u00ae radio-conjugates (BRCs) for multiple agreed upon oncology targets.<\/span><\/p>\n<p>\u201cThis collaboration builds on the groundbreaking clinical work we have been doing in the toxin conjugate field and provides new and additional validation for this unique technology,\u201d\u00a0<strong>said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.<\/strong> \u201cWe look forward to working closely with Novartis to pioneer the discovery and development of potential new cutting-edge radiopharmaceutical cancer treatments based on Bicycles. We believe the properties of Bicycles make them well suited for the development of precision guided radiopharmaceuticals and represents the next leg in the application of our proprietary discovery platform in oncology.\u201d<\/p>\n<p>Under the terms of the agreement, Bicycle will utilize its proprietary phage platform to discover Bicycles to be developed into BRCs. Novartis will be responsible for further development, manufacture and commercialization of the BRCs. Novartis will fund all pre-clinical and clinical development and commercialization activities. Bicycle will receive a $50 million upfront payment and is eligible for development and commercial-based milestone payments totaling up to $1.7 billion. Bicycle will also be eligible to receive tiered royalties on Bicycle-based medicines commercialized by Novartis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radioligand therapies in oncology Bicycle will receive a $50 million upfront payment as well as potential milestones and tiered commercial royalties Bicycle Therapeutics\u00a0plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":1324,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[6,29],"tags":[50],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bicycle Therapeutics announces a strategic collaboration with Novartis - Cambridge Innovation Capital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicycle Therapeutics announces a strategic collaboration with Novartis - Cambridge Innovation Capital\" \/>\n<meta property=\"og:description\" content=\"Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radioligand therapies in oncology Bicycle will receive a $50 million upfront payment as well as potential milestones and tiered commercial royalties Bicycle Therapeutics\u00a0plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/\" \/>\n<meta property=\"og:site_name\" content=\"Cambridge Innovation Capital\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T09:37:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-16T12:13:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-BCYC-IPO-Tower-Campaign-Photo-2-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"2049\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Colin Berwick\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:site\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Colin Berwick\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/\",\"url\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/\",\"name\":\"Bicycle Therapeutics announces a strategic collaboration with Novartis - Cambridge Innovation Capital\",\"isPartOf\":{\"@id\":\"https:\/\/www.cic.vc\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-BCYC-IPO-Tower-Campaign-Photo-2-scaled.jpg\",\"datePublished\":\"2023-03-28T09:37:16+00:00\",\"dateModified\":\"2024-04-16T12:13:24+00:00\",\"author\":{\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/2a0fb039a2a216c26fcd56ba96b54734\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#primaryimage\",\"url\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-BCYC-IPO-Tower-Campaign-Photo-2-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-BCYC-IPO-Tower-Campaign-Photo-2-scaled.jpg\",\"width\":2560,\"height\":2049},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cic.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicycle Therapeutics announces a strategic collaboration with Novartis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cic.vc\/#website\",\"url\":\"https:\/\/www.cic.vc\/\",\"name\":\"Cambridge Innovation Capital\",\"description\":\"We enable visionaries to build global, category-leading companies.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cic.vc\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/2a0fb039a2a216c26fcd56ba96b54734\",\"name\":\"Colin Berwick\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e7f6d32e9af553e4e969350cc5adddbb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e7f6d32e9af553e4e969350cc5adddbb?s=96&d=mm&r=g\",\"caption\":\"Colin Berwick\"},\"url\":\"https:\/\/www.cic.vc\/author\/colin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicycle Therapeutics announces a strategic collaboration with Novartis - Cambridge Innovation Capital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/","og_locale":"en_GB","og_type":"article","og_title":"Bicycle Therapeutics announces a strategic collaboration with Novartis - Cambridge Innovation Capital","og_description":"Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radioligand therapies in oncology Bicycle will receive a $50 million upfront payment as well as potential milestones and tiered commercial royalties Bicycle Therapeutics\u00a0plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide [&hellip;]","og_url":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/","og_site_name":"Cambridge Innovation Capital","article_published_time":"2023-03-28T09:37:16+00:00","article_modified_time":"2024-04-16T12:13:24+00:00","og_image":[{"width":2560,"height":2049,"url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-BCYC-IPO-Tower-Campaign-Photo-2-scaled.jpg","type":"image\/jpeg"}],"author":"Colin Berwick","twitter_card":"summary_large_image","twitter_creator":"@cic_vc","twitter_site":"@cic_vc","twitter_misc":{"Written by":"Colin Berwick","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/","url":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/","name":"Bicycle Therapeutics announces a strategic collaboration with Novartis - Cambridge Innovation Capital","isPartOf":{"@id":"https:\/\/www.cic.vc\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#primaryimage"},"image":{"@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-BCYC-IPO-Tower-Campaign-Photo-2-scaled.jpg","datePublished":"2023-03-28T09:37:16+00:00","dateModified":"2024-04-16T12:13:24+00:00","author":{"@id":"https:\/\/www.cic.vc\/#\/schema\/person\/2a0fb039a2a216c26fcd56ba96b54734"},"breadcrumb":{"@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#primaryimage","url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-BCYC-IPO-Tower-Campaign-Photo-2-scaled.jpg","contentUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-BCYC-IPO-Tower-Campaign-Photo-2-scaled.jpg","width":2560,"height":2049},{"@type":"BreadcrumbList","@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-and-commercialize-bicycle-radio-conjugates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cic.vc\/"},{"@type":"ListItem","position":2,"name":"Bicycle Therapeutics announces a strategic collaboration with Novartis"}]},{"@type":"WebSite","@id":"https:\/\/www.cic.vc\/#website","url":"https:\/\/www.cic.vc\/","name":"Cambridge Innovation Capital","description":"We enable visionaries to build global, category-leading companies.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cic.vc\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/2a0fb039a2a216c26fcd56ba96b54734","name":"Colin Berwick","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e7f6d32e9af553e4e969350cc5adddbb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e7f6d32e9af553e4e969350cc5adddbb?s=96&d=mm&r=g","caption":"Colin Berwick"},"url":"https:\/\/www.cic.vc\/author\/colin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/457"}],"collection":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/comments?post=457"}],"version-history":[{"count":7,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/457\/revisions"}],"predecessor-version":[{"id":2995,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/457\/revisions\/2995"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media\/1324"}],"wp:attachment":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media?parent=457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/categories?post=457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/tags?post=457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}